Close Menu

Clinical Data's sale of its genomic services unit to Beckman Coulter will not affect its pharmacogenomics efforts, but will enable it to better focus on its drug development and biomarker discovery programs, the company says.

Beckman Coulter's acquisition of Clinical Data's Cogenics business for around $17 million, announced this spring, "will have no impact on our focus as a pharmacogenomics company," according to Clinical Data CEO Drew Fromkin.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

GenomeWeb Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives

Never miss another important industry story.

Try GenomeWeb Premium now.

You may already have institutional access!

Check if I qualify.

Already a GenomeWeb or 360Dx Premium member?
Login Now.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

In a cartoon, Vox explores the lack of women among this year's winners of the Nobel Prize.

Science reports a new US defense bill would establish two groups aimed at combating foreign influence on research. 

Nature Biotechnology discusses promising early results from two clinical trials of CRISPR-based therapy for β-thalassemia and sickle cell disease.

In Cell this week: analysis of tissue clones, metagenomic studies of ocean water samples, and more.